Background Optimal antimicrobial drug exposure in the lung is required for successful
treatment outcomes for nosocomial pneumonia. Little is known about the intrapulmonary …

Background The aim of the study was to describe the population pharmacokinetics (PK) of
meropenem in critically ill patients receiving sustained low-efficiency dialysis (SLED) …

Background Severe bacterial infections remain a major challenge in intensive care units
because of their high prevalence and mortality. Adequate antibiotic exposure has been …

Introduction The scope of extracorporeal membrane oxygenation (ECMO) is expanding;
however, optimal drug prescription during ECMO remains a developing science. Currently …

Introduction Meropenem bactericidal activity depends on the time when the free drug
concentrations remain above the minimum inhibitory concentration of pathogens. The goal …

Background Ventriculitis is a complication of temporary intraventricular drains. The limited
penetration of meropenem into the cerebrospinal fluid (CSF) is well known. However …

Background Correct antibiotic dosing remains a challenge for the clinician. The aim of this
study was to assess the influence of augmented renal clearance on pharmacokinetic …

Background The randomized, double-blind, phase 3 ASPECT-NP trial evaluated the efficacy
of 3 g of ceftolozane/tazobactam (C/T) versus 1 g of meropenem infused every 8 h for 8 to 14 …

Background Colistin is recommended in the empirical treatment of ventilator-associated
pneumonia (VAP) with a high prevalence of carbapenem-resistant gram-negative bacilli (CR …

Objectives The objective of this study was to propose an optimal treatment regimen of
meropenem in critically ill patients with severe nosocomial pneumonia. Patients and …